Paragon 28 Acquires the Assets of Additive Orthopaedics

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Paragon 28, Inc., a market-leading orthopedic medical device company focused exclusively on the foot-and-ankle, today announced that the Company has acquired the product lines of Additive Orthopaedics (“Additive”).

The Additive 3D-printed Patient Specific Talus Spacer was approved on February 17, 2021 by the US Food and Drug Administration (“FDA”) and is the first and only patient-specific total talus replacement implant authorized for use in the United States. The FDA approved the implant as a humanitarian use device. It is designed to replace the talus, the bone in the ankle that connects the leg and foot. The Additive implant provides patients access to a novel, joint-sparing alternative to traditional ankle fusion therapies.

Also acquired as part of the transaction was Additive’s internally developed, proprietary pre-operative surgical planning application to assist in surgical planning.  The application is an end-to-end, fully integrated cloud-based communication tool that aligns surgeons and engineers to design patient specific surgical plans and implants, optimizing patient outcomes.

“The addition of the Additive Orthopaedics product portfolio and surgical planning capabilities provides Paragon 28 customers exclusive access to the only FDA-approved patient specific total talus replacement implant,” said Albert DaCosta, Co-Founder and Chief Executive Officer of Paragon 28. “The Additive acquisition also significantly accelerates the Company’s strategy to leverage smart tools, artificial intelligence and advanced technology to improve patient outcomes.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.